Docetaxel treatment in castration-resistant prostate cancer: the triad gene-drug-disease
- PMID: 21296995
- DOI: 10.1210/jc.2010-2875
Docetaxel treatment in castration-resistant prostate cancer: the triad gene-drug-disease
Comment on
-
Estrogen receptor α and aromatase polymorphisms affect risk, prognosis, and therapeutic outcome in men with castration-resistant prostate cancer treated with docetaxel-based therapy.J Clin Endocrinol Metab. 2011 Feb;96(2):E368-72. doi: 10.1210/jc.2010-2070. Epub 2010 Nov 24. J Clin Endocrinol Metab. 2011. PMID: 21106711 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
